Leo International Group Makes History with Frankfurt Stock Exchange Listing, Expands Precision Health Strategy Globally

Leo International Group has acquired a controlling stake in SPOABG AG, renaming it Leo International Precision Health AG. This marks the first time a Taiwanese-founded enterprise has listed on Germany's Frankfurt Stock Exchange. The move is part of Leo International's global expansion strategy to advance AI-powered precision health. The company's Precision Health Trinity strategy integrates AI-driven drug discovery, diagnostics, and community-focused medical services.

Leo International Group, a Taiwanese family-owned enterprise, has made a significant move in its global expansion strategy by acquiring a controlling stake in SPOABG AG and renaming it Leo International Precision Health AG (LIPH AG). This marks the first time a Taiwanese-founded enterprise has achieved mainboard listing status on Germany's prestigious Frankfurt Stock Exchange [1].

The acquisition, announced on May 27, 2025, is part of Leo International's broader strategy to advance AI-powered precision health. The company's new listing on the Frankfurt Stock Exchange will serve as a springboard for scaling its AI-driven healthcare strategy, known as the "Precision Health Trinity" [1]. This strategy integrates AI-driven drug discovery, AI-enabled diagnostics, and community-focused medical services through smart clinics.

Leo International Group, founded in 1926, has a mission rooted in "Caring for People, Advancing Humanity." With its diverse portfolio spanning biomedical innovation, wealth succession, and high-end lifestyle services, the company aims to leverage the Frankfurt Stock Exchange's robust market capitalization and leading financial centers to drive innovation and create lasting value for all stakeholders [1].

The Frankfurt Stock Exchange, part of the Deutsche Börse Group, boasts a market capitalization of EUR 1.97 trillion and is one of the world's leading financial centers. In 2024 alone, Germany's biotech and medtech sectors attracted EUR 1.6 billion in investment, a 70% year-on-year surge [1]. As global healthcare shifts towards digitization, the digital pathology market is forecast to grow from USD 8.1 billion in 2024 to USD 19.5 billion by 2031, making Frankfurt an ideal launchpad for Leo International's Precision Health Trinity [1].

Parallel to the Frankfurt expansion, Leo International announced the establishment of a Single Family Office (SFO) in Singapore. This office will manage multigenerational capital while aligning with the Group's long-term vision for social impact and wealth succession. Singapore, with its political stability, transparent regulation, and attractive tax environment, has emerged as Asia's premier family office hub, now home to over 2,000 SFOs [1].

LIPH AG will serve as a public investment vehicle for Leo International to drive its non-organic growth strategy. By acquiring and integrating AI-health companies across Europe and Asia, the Group seeks to rapidly scale operations, unlock synergies, and boost shareholder value. Leo International plans to attract sovereign wealth funds and global investors, leveraging fair valuation mechanisms in capital markets to build a robust, cross-border precision health platform [1].

The acquisition of LIPH AG marks a pivotal milestone in Leo International's global strategic expansion. With 80% equity in the newly renamed Frankfurt-listed firm, the Group's Chairman, Leo Wang, and original shareholders are transitioning their stakes to gain full access to international capital markets, in accordance with German legal and accounting standards [1].

Leo International's journey from a Taiwanese family business to a global leader in health-tech exemplifies a unique fusion of heritage and innovation. Rooted in values shaped over four generations, the Group's current trajectory is driven by industrial relevance, cutting-edge technology, and social purpose [1].

References:
[1] https://www.insiderecent.com/leo-international-leaps-from-lion-city-to-frankfurt-with-ai-precision-health-listing-53707.html